Key result
Genetically lowered Lp(a) linked to ~29% lower CHD risk per SD.
Why the study?
Does genetically lowered plasma lipoprotein(a) reduce the risk of coronary heart disease and other cardiometabolic or non-cardiovascular disorders in individuals of European ancestry?
Observational (n=112,338)
Yes
Does genetically lowered plasma lipoprotein(a) reduce the risk of coronary heart disease and other cardiometabolic or non-cardiovascular disorders in individuals of European ancestry?
Answers are grounded in this paper and cite their sources.
Genetically lowered Lp(a) is associated with proportional reductions in coronary heart disease, peripheral vascular disease, stroke, heart failure, aortic stenosis, and renal dysfunction without increasing the risk of diabetes or cancer, supporting pharmacological Lp(a) lowering across multiple atherosclerotic and valvular conditions.
BACKGROUND Genomic analyses have suggested that the LPA gene and its associated plasma biomarker, lipoprotein(a) (Lp[a]), represent a causal risk factor for coronary heart disease (CHD). As such, lowering Lp(a) has emerged as a therapeutic strategy. Beyond target identification, human genetics may contribute to the development of new therapies by defining the full spectrum of beneficial and adverse consequences and by developing a dose-response curve of target perturbation. OBJECTIVES We attempted to establish the full phenotypic impact of LPA gene variation and to estimate a dose-response curve between genetically altered plasma Lp(a) and risk for CHD. METHODS We leveraged genetic variants at the LPA gene from 3 data sources: individual-level data from 112,338 participants in the UK Biobank; summary association results from large-scale genome-wide association studies; and LPA gene sequencing results from cases with and controls free of CHD. RESULTS One standard deviation genetically lowered Lp(a) level was associated with 29% lower risk of CHD (odds ratio [OR]: 0.71; 95% confidence interval [CI]: 0.69 to 0.73), 31% lower risk of peripheral vascular disease (OR: 0.69; 95% CI: 0.59 to 0.80), 13% lower risk of stroke (OR: 0.87; 95% CI: 0.79 to 0.96), 17% lower risk of heart failure (OR: 0.83; 95% CI: 0.73 to 0.94), and 37% lower risk of aortic stenosis (OR: 0.63; 95% CI: 0.47 to 0.83). We observed no association with 31 other disorders including type 2 diabetes and cancer. Variants that led to gain of LPA gene function increased risk for CHD whereas those that led to loss of gene function reduced CHD risk. CONCLUSIONS Beyond CHD, genetically lowered Lp(a) is associated with a lower risk of peripheral vascular disease, stroke, heart failure, and aortic stenosis. As such, pharmacological lowering of plasma Lp(a) may impact a range of atherosclerosis-related diseases.
No takes yet. Share an insight, caveat, or question.
Emdin et al. (2016) conducted an observational in Cardiometabolic diseases (including coronary heart disease, peripheral vascular disease, stroke, heart failure, and aortic stenosis) (n=112,338). Genetically lowered lipoprotein(a) (1 standard deviation decrease [0.332 μmol/l] via a 4-SNP LPA gene variant score) vs. Higher genetically predicted lipoprotein(a) levels (per 1 SD increase) or non-carriers of LPA loss-of-function variants was evaluated on Coronary heart disease (CHD) (OR 0.71, 95% CI 0.69 to 0.73, p=3.2x10^-90). A 1 SD genetically lowered Lp(a) level was associated with a 29% lower risk of coronary heart disease as well as lower risks of PVD, stroke, HF, and AS.
Synapse has enriched 10 related papers. Consider them for comparative context: